Dapeng Wu, MD, PhD

Articles by Dapeng Wu, MD, PhD

Comparison of the 3 Most Commonly Used Modified PD-1 Inhibitors Plus Chemotherapy in Inoperable Wild-Type Non–Small Cell Lung Cancer

ByDapeng Wu, MD, PhD,Juanjuan Cui, MD,Wenjing Zhum MD, PhD,Tao Qin, MD,Hanlin Xu, MD

March 20th 2026

Although survival outcomes were comparable among the 3 PD-1 inhibitors in the overall cohort, tislelizumab and sintilimab showed superior PFS in PD-L1–positive subgroups, suggesting biomarker-driven therapeutic selection.

Latest Updated Articles

Dapeng Wu, MD, PhD

Articles by Dapeng Wu, MD, PhD

Comparison of the 3 Most Commonly Used Modified PD-1 Inhibitors Plus Chemotherapy in Inoperable Wild-Type Non–Small Cell Lung Cancer

Latest Updated Articles

Trending on CancerNetwork

FDA Grants Fast Track Designation to FG001 for High-Grade Glioma Surgery

Potential Rusfertide Approval May Offer More Control of Polycythemia Vera

FDA Approves Companion Diagnostic for Niraparib in Advanced Ovarian Cancer

NCCN Guidelines Add Novel Therapeutics to First-Line TNBC Armamentarium

Liquid Biopsies, Blood-Based MCED Tests for Detecting CRC in Young Patients